A particularly difficult clinical issue is that MLL-r B-ALL retains lineage plasticity and infidelity—following treatment with CD19 CAR T-cell therapy or monoclonal antibodies MLL-AF4 ALL can undergo a lineage switch [7]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.